<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184440</url>
  </required_header>
  <id_info>
    <org_study_id>QQLY2019</org_study_id>
    <nct_id>NCT04184440</nct_id>
  </id_info>
  <brief_title>The Hypoglycemic Effect of Cyclocarya Paliurus Extract on Hyperglycemic Populations</brief_title>
  <official_title>The Hypoglycemic Effect of Cyclocarya Paliurus Extract on Hyperglycemic Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind controlled trial，aiming to investigate the hypoglycemic
      effect of Cyclocarya paliurus extract and Cyclocarya paliurus compounds on hyperglycemic
      populations without modifying their original treatment plans.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be divided randomly into three groups，among which the intervention will start and end simultaneously.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The allocation of three groups is completed by the primary researcher,and unknown to participants and other reachers. It is the same in the size,color,shape and taste of capsules administrated by three groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>changes of FPG</measure>
    <time_frame>at 0 week，4th week and 12th week in the intervention period</time_frame>
    <description>fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of HbA1c</measure>
    <time_frame>at 0 week，4th week and 12th week in the intervention period</time_frame>
    <description>glycated hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of fasting insulin</measure>
    <time_frame>at 0 week，4th week and 12th week in the intervention period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of OGTT</measure>
    <time_frame>at 0 week，4th week and 12th week in the intervention period</time_frame>
    <description>oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of blood lipids</measure>
    <time_frame>at 0 week，4th week and 12th week in the intervention period</time_frame>
    <description>total cholesterol，high density lipoprotein cholesterol，low density lipoprotein cholesterol，triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of gut microbiota</measure>
    <time_frame>at 0 week，4th week and 12th week in the intervention period</time_frame>
    <description>16s RNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of short chain fatty acids</measure>
    <time_frame>at 0 week，4th week and 12th week in the intervention period</time_frame>
    <description>metabolites of microbiota in feces</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>corn starch；capsule，2 g/day，2 times/day；3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclocarya paliurus extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aqueous extract of Cyclocarya paliurus；capsule，2 g/day，2 times/day；3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclocarya paliurus compounds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mixed aqueous extract of Cyclocarya paliurus and other traditional Chinese herbal medicines including Astragalus propinquus Schischkin，Dioscorea oppositifolia L.，Dendrobium nobile Lindl.，Salvia miltiorrhiza Bge. and Inulin；capsule，2 g/day，2 times/day；3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cyclocarya paliurus extract</intervention_name>
    <description>The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .</description>
    <arm_group_label>Cyclocarya paliurus extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cyclocarya paliurus compounds</intervention_name>
    <description>The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .</description>
    <arm_group_label>Cyclocarya paliurus compounds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The participants are divided randomly into three groups，one of which are asked to take placebo for three months .</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pre-diabetic or type 2 diabetic patients who are treated with only one oral
             antidiabetic agent and whose fasting plasma glucose is lower than 8.4 mmol;

          -  age:20-65 years;

          -  BMI :20-35kg/m2.

        Exclusion Criteria:

          -  type 1 diabetic patients;

          -  type 2 diabetic patients with insulin treatment；

          -  pregnant or lactating women；

          -  adverse effect on intervention；

          -  acute or chronic inflammatory conditions;

          -  severe hepatic,kidney or other complications;

          -  other situations ineligible to intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liegang Liu, PhD</last_name>
    <phone>+86-27-83650522</phone>
    <email>liegangliu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongjie Liu, master</last_name>
    <email>D201981405@hust.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shiyan Taihe Hospital</name>
      <address>
        <city>Shiyan</city>
        <state>Hubei</state>
        <zip>442008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liegang Liu, PhD</last_name>
      <phone>+86-27-83650522</phone>
      <email>liegangliu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hongjei Liu, master</last_name>
      <email>D201981405@hust.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>December 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Liegang Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cyclocarya paliurus extract</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>pre-diabetes and diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

